1165-38-4 Usage
General Description
2,3-Seco-5-androstan-17-one-2,3-dicarboxylic acid is a chemical compound with a complex molecular structure that includes a 2,3-seco-5-androstan-17-one backbone and two carboxylic acid functional groups. It is a steroid derivative that has potential applications in the fields of medicinal chemistry and drug discovery. The compound's unique structure and functional groups make it a promising candidate for the development of new pharmaceuticals, particularly in the treatment of hormonal disorders and related conditions. Additionally, it may also be of interest to researchers in the fields of organic synthesis and chemical biology due to its unprecedented molecular architecture and synthetic challenges. Further study and research into the properties and potential uses of 2,3-Seco-5-androstan-17-one-2,3-dicarboxylic acid could lead to the development of novel drugs and therapeutic agents with diverse medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1165-38-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,6 and 5 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1165-38:
(6*1)+(5*1)+(4*6)+(3*5)+(2*3)+(1*8)=64
64 % 10 = 4
So 1165-38-4 is a valid CAS Registry Number.
InChI:InChI=1/C19H28O5/c1-18-8-7-14-12(13(18)5-6-15(18)20)4-3-11(9-16(21)22)19(14,2)10-17(23)24/h11-14H,3-10H2,1-2H3,(H,21,22)(H,23,24)
1165-38-4Relevant articles and documents
Steroidal nitrone inhibitors of 5α-reductase
Robinson, Andrea J.,DeLucca, Indawati,Drummond, Spencer,Boswell, George A.
, p. 4801 - 4804 (2003)
This paper describes the rational design and synthesis of novel inhibitors of human steroid 5α-reductase. Steroidal nitrones were synthesised via an eight-step sequence from epiandrosterone and were tested for activity against type I and II 5α-reductase isozymes. Judicious placement of the nitrone into the steroid A-ring provided an effective and stable transition-state mimic of the postulated enolate intermediate involved in the conversion of testosterone into dihydrotestosterone.
NOVEL CYP17 INHIBITORS
-
Page/Page column 110-111, (2011/08/04)
Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.